Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

Benzinga Newsdesk www.benzinga.com Positive 71.2%

Neg 0% Neu 0% Pos 71.2%

Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.